HIPEC with CRS versus cytoreductive surgery (CRS) for the gastric cancer metastasis to peritoneum

Clin Transl Oncol. 2023 Apr;25(4):1011-1016. doi: 10.1007/s12094-022-03004-5. Epub 2022 Nov 18.

Abstract

Background: Peritoneal metastases (PM) have a poor prognosis in gastric cancer (GC). Cytoreductive surgery (CRS) gives favorable outcomes, but the influence of hyperthermic intraperitoneal chemotherapy (HIPEC) remains contentious. We designed to distinguish results between CRS versus HIPEC-CRS in patients with peritoneal metastases from gastric cancer.

Materials and methods: PubMed, Scopus, Embase and Cochrane library accessed to collect data and language is restricted to English. RevMan 5.4 was used to perform statistical analysis. The outcomes for categorical variables are mentioned in the risk ratio.

Results: Ten trials involving 1367 patients in which 707 were CRS-HIPEC, while 660 CRS. We got significant results in 3rd year survival (P < 0.05), while 1st and 5th years are not statistically significant P > 0.05.

Conclusion: To compare with CRS, CRS-HIPEC has improved survival rate in deprived of further morbidity or mortality.

Keywords: Gastrectomy and gastric cancer; Hyperthermic intraperitoneal chemotherapy; Peritoneal metastasis.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Cytoreduction Surgical Procedures / methods
  • Humans
  • Hyperthermia, Induced* / methods
  • Hyperthermic Intraperitoneal Chemotherapy
  • Peritoneal Neoplasms* / secondary
  • Peritoneum
  • Stomach Neoplasms* / pathology
  • Survival Rate